{"id":"https://openalex.org/W4416740916","doi":"https://doi.org/10.1158/1535-7163.30734135","title":"Supplementary Data from The Bispecific Tumor Antigen-Conditional 4\u20131BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies","display_name":"Supplementary Data from The Bispecific Tumor Antigen-Conditional 4\u20131BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies","publication_year":2025,"publication_date":"2025-11-27","ids":{"openalex":"https://openalex.org/W4416740916","doi":"https://doi.org/10.1158/1535-7163.30734135"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.30734135","doi":"https://doi.org/10.1158/1535-7163.30734135","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.30734135","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Data_from_The_Bispecific_Tumor_Antigen-Conditional_4_1BB_x_5T4_Agonist_ALG_APV-527_Mediates_Strong_T-Cell_Activation_and_Potent_Antitumor_Activity_in_Preclinical_Studies/30734135/1/files/59895989.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Data_from_The_Bispecific_Tumor_Antigen-Conditional_4_1BB_x_5T4_Agonist_ALG_APV-527_Mediates_Strong_T-Cell_Activation_and_Potent_Antitumor_Activity_in_Preclinical_Studies/30734135/1/files/59895989.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5070508749","display_name":"Michelle Hase Nelson","orcid":"https://orcid.org/0000-0001-7597-0923","observed_orcids":["https://orcid.org/0000-0001-7597-0923"]},"institutions":[{"id":"https://openalex.org/I4210122457","display_name":"Aptevo Therapeutics (United states)","ror":"https://ror.org/02k8zdn75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michelle H. Nelson","raw_affiliation_strings":["Aptevo Therapeutics Inc. , Seattle , Washington , USA"],"raw_orcid":"https://orcid.org/0000-0001-7597-0923","affiliations":[{"raw_affiliation_string":"Aptevo Therapeutics Inc. , Seattle , Washington , USA","institution_ids":["https://openalex.org/I4210122457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034448965","display_name":"Sara Fritzell","orcid":"https://orcid.org/0000-0003-1079-2614","observed_orcids":["https://orcid.org/0000-0003-1079-2614"]},"institutions":[{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Sara Fritzell","raw_affiliation_strings":["Alligator Bioscience AB , Lund , Sweden"],"raw_orcid":"https://orcid.org/0000-0003-1079-2614","affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB , Lund , Sweden","institution_ids":["https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046183852","display_name":"Robert E. Miller","orcid":"https://orcid.org/0000-0001-7236-3204","observed_orcids":["https://orcid.org/0000-0001-7236-3204"]},"institutions":[{"id":"https://openalex.org/I4210122457","display_name":"Aptevo Therapeutics (United states)","ror":"https://ror.org/02k8zdn75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Miller","raw_affiliation_strings":["Aptevo Therapeutics Inc. , Seattle , Washington , USA"],"raw_orcid":"https://orcid.org/0000-0001-7236-3204","affiliations":[{"raw_affiliation_string":"Aptevo Therapeutics Inc. , Seattle , Washington , USA","institution_ids":["https://openalex.org/I4210122457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025033564","display_name":"Doreen Werchau","orcid":"https://orcid.org/0000-0002-6913-837X","observed_orcids":["https://orcid.org/0000-0002-6913-837X"]},"institutions":[{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Doreen Werchau","raw_affiliation_strings":["Alligator Bioscience AB , Lund , Sweden"],"raw_orcid":"https://orcid.org/0000-0002-6913-837X","affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB , Lund , Sweden","institution_ids":["https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009704800","display_name":"Danielle Van Citters","orcid":"https://orcid.org/0000-0001-6599-5190","observed_orcids":["https://orcid.org/0000-0001-6599-5190"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Danielle Van Citters","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6599-5190","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021639097","display_name":"Anneli Nilsson","orcid":"https://orcid.org/0000-0002-2468-4035","observed_orcids":["https://orcid.org/0000-0002-2468-4035"]},"institutions":[{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Anneli Nilsson","raw_affiliation_strings":["Alligator Bioscience AB , Lund , Sweden"],"raw_orcid":"https://orcid.org/0000-0002-2468-4035","affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB , Lund , Sweden","institution_ids":["https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005698426","display_name":"Lynda Misher","orcid":"https://orcid.org/0000-0002-5071-7857","observed_orcids":["https://orcid.org/0000-0002-5071-7857"]},"institutions":[{"id":"https://openalex.org/I4210122457","display_name":"Aptevo Therapeutics (United states)","ror":"https://ror.org/02k8zdn75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lynda Misher","raw_affiliation_strings":["Aptevo Therapeutics Inc. , Seattle , Washington , USA"],"raw_orcid":"https://orcid.org/0000-0002-5071-7857","affiliations":[{"raw_affiliation_string":"Aptevo Therapeutics Inc. , Seattle , Washington , USA","institution_ids":["https://openalex.org/I4210122457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070016509","display_name":"Lill Ljung","orcid":"https://orcid.org/0000-0003-4810-8136","observed_orcids":["https://orcid.org/0000-0003-4810-8136"]},"institutions":[{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Lill Ljung","raw_affiliation_strings":["Alligator Bioscience AB , Lund , Sweden"],"raw_orcid":"https://orcid.org/0000-0003-4810-8136","affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB , Lund , Sweden","institution_ids":["https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025610289","display_name":"Robert Bader","orcid":"https://orcid.org/0000-0002-6378-8566","observed_orcids":["https://orcid.org/0000-0002-6378-8566"]},"institutions":[{"id":"https://openalex.org/I4210122457","display_name":"Aptevo Therapeutics (United states)","ror":"https://ror.org/02k8zdn75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Bader","raw_affiliation_strings":["Aptevo Therapeutics Inc. , Seattle , Washington , USA"],"raw_orcid":"https://orcid.org/0000-0002-6378-8566","affiliations":[{"raw_affiliation_string":"Aptevo Therapeutics Inc. , Seattle , Washington , USA","institution_ids":["https://openalex.org/I4210122457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066837870","display_name":"Adnan Deronic","orcid":"https://orcid.org/0000-0001-8041-2037","observed_orcids":["https://orcid.org/0000-0001-8041-2037"]},"institutions":[{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Adnan Deronic","raw_affiliation_strings":["Alligator Bioscience AB , Lund , Sweden"],"raw_orcid":"https://orcid.org/0000-0001-8041-2037","affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB , Lund , Sweden","institution_ids":["https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029423589","display_name":"Allison Given Chunyk","orcid":"https://orcid.org/0000-0002-3000-1501","observed_orcids":["https://orcid.org/0000-0002-3000-1501"]},"institutions":[{"id":"https://openalex.org/I4210122457","display_name":"Aptevo Therapeutics (United states)","ror":"https://ror.org/02k8zdn75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Allison G. Chunyk","raw_affiliation_strings":["Aptevo Therapeutics Inc. , Seattle , Washington , USA"],"raw_orcid":"https://orcid.org/0000-0002-3000-1501","affiliations":[{"raw_affiliation_string":"Aptevo Therapeutics Inc. , Seattle , Washington , USA","institution_ids":["https://openalex.org/I4210122457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062215638","display_name":"Lena Schultz","orcid":"https://orcid.org/0000-0001-8394-5189","observed_orcids":["https://orcid.org/0000-0001-8394-5189"]},"institutions":[{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Lena Schultz","raw_affiliation_strings":["Alligator Bioscience AB , Lund , Sweden"],"raw_orcid":"https://orcid.org/0000-0001-8394-5189","affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB , Lund , Sweden","institution_ids":["https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008420464","display_name":"Laura A. Varas","orcid":"https://orcid.org/0000-0001-8083-0888","observed_orcids":["https://orcid.org/0000-0001-8083-0888"]},"institutions":[{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Laura A. Varas","raw_affiliation_strings":["Alligator Bioscience AB , Lund , Sweden"],"raw_orcid":"https://orcid.org/0000-0001-8083-0888","affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB , Lund , Sweden","institution_ids":["https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027352248","display_name":"Nadia Rose","orcid":"https://orcid.org/0000-0002-8729-064X","observed_orcids":["https://orcid.org/0000-0002-8729-064X"]},"institutions":[{"id":"https://openalex.org/I4210092524","display_name":"SARomics Biostructures (Sweden)","ror":"https://ror.org/00md1r011","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210092524"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Nadia Rose","raw_affiliation_strings":["Saromics Biostructures AB , Lund , Sweden"],"raw_orcid":"https://orcid.org/0000-0002-8729-064X","affiliations":[{"raw_affiliation_string":"Saromics Biostructures AB , Lund , Sweden","institution_ids":["https://openalex.org/I4210092524"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009481643","display_name":"M. H\u00e5kansson","orcid":"https://orcid.org/0000-0002-7264-6316","observed_orcids":["https://orcid.org/0000-0002-7264-6316"]},"institutions":[{"id":"https://openalex.org/I4210092524","display_name":"SARomics Biostructures (Sweden)","ror":"https://ror.org/00md1r011","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210092524"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Maria H\u00e5kansson","raw_affiliation_strings":["Saromics Biostructures AB , Lund , Sweden"],"raw_orcid":"https://orcid.org/0000-0002-7264-6316","affiliations":[{"raw_affiliation_string":"Saromics Biostructures AB , Lund , Sweden","institution_ids":["https://openalex.org/I4210092524"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074332251","display_name":"Jane A. Gross","orcid":"https://orcid.org/0000-0001-7755-8772","observed_orcids":["https://orcid.org/0000-0001-7755-8772"]},"institutions":[{"id":"https://openalex.org/I4210122457","display_name":"Aptevo Therapeutics (United states)","ror":"https://ror.org/02k8zdn75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jane Gross","raw_affiliation_strings":["Aptevo Therapeutics Inc. , Seattle , Washington , USA"],"raw_orcid":"https://orcid.org/0000-0001-7755-8772","affiliations":[{"raw_affiliation_string":"Aptevo Therapeutics Inc. , Seattle , Washington , USA","institution_ids":["https://openalex.org/I4210122457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038303467","display_name":"Christina Furebring","orcid":"https://orcid.org/0000-0002-6680-1543","observed_orcids":["https://orcid.org/0000-0002-6680-1543"]},"institutions":[{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Christina Furebring","raw_affiliation_strings":["Alligator Bioscience AB , Lund , Sweden"],"raw_orcid":"https://orcid.org/0000-0002-6680-1543","affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB , Lund , Sweden","institution_ids":["https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064689071","display_name":"Peter Pavlik","orcid":"https://orcid.org/0000-0002-1218-0331","observed_orcids":["https://orcid.org/0000-0002-1218-0331"]},"institutions":[{"id":"https://openalex.org/I4210122457","display_name":"Aptevo Therapeutics (United states)","ror":"https://ror.org/02k8zdn75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter Pavlik","raw_affiliation_strings":["Aptevo Therapeutics Inc. , Seattle , Washington , USA"],"raw_orcid":"https://orcid.org/0000-0002-1218-0331","affiliations":[{"raw_affiliation_string":"Aptevo Therapeutics Inc. , Seattle , Washington , USA","institution_ids":["https://openalex.org/I4210122457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073829192","display_name":"Anette Sundstedt","orcid":"https://orcid.org/0000-0001-9216-1386","observed_orcids":["https://orcid.org/0000-0001-9216-1386"]},"institutions":[{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Anette Sundstedt","raw_affiliation_strings":["Alligator Bioscience AB , Lund , Sweden"],"raw_orcid":"https://orcid.org/0000-0001-9216-1386","affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB , Lund , Sweden","institution_ids":["https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072741407","display_name":"Niina Veitonm\u00e4ki","orcid":"https://orcid.org/0000-0001-6933-0823","observed_orcids":["https://orcid.org/0000-0001-6933-0823"]},"institutions":[{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Niina Veitonm\u00e4ki","raw_affiliation_strings":["Alligator Bioscience AB , Lund , Sweden"],"raw_orcid":"https://orcid.org/0000-0001-6933-0823","affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB , Lund , Sweden","institution_ids":["https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005113342","display_name":"Hilario J. Ramos","orcid":"https://orcid.org/0000-0003-3958-2725","observed_orcids":["https://orcid.org/0000-0003-3958-2725"]},"institutions":[{"id":"https://openalex.org/I4210122457","display_name":"Aptevo Therapeutics (United states)","ror":"https://ror.org/02k8zdn75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hilario J. Ramos","raw_affiliation_strings":["Aptevo Therapeutics Inc. , Seattle , Washington , USA"],"raw_orcid":"https://orcid.org/0000-0003-3958-2725","affiliations":[{"raw_affiliation_string":"Aptevo Therapeutics Inc. , Seattle , Washington , USA","institution_ids":["https://openalex.org/I4210122457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003121489","display_name":"Anna S\u00e4ll","orcid":"https://orcid.org/0000-0001-5287-2984","observed_orcids":["https://orcid.org/0000-0001-5287-2984"]},"institutions":[{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Anna S\u00e4ll","raw_affiliation_strings":["Alligator Bioscience AB , Lund , Sweden"],"raw_orcid":"https://orcid.org/0000-0001-5287-2984","affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB , Lund , Sweden","institution_ids":["https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002749401","display_name":"Anna Dahlman","orcid":"https://orcid.org/0000-0002-5092-5752","observed_orcids":["https://orcid.org/0000-0002-5092-5752"]},"institutions":[{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Anna Dahlman","raw_affiliation_strings":["Alligator Bioscience AB , Lund , Sweden"],"raw_orcid":"https://orcid.org/0000-0002-5092-5752","affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB , Lund , Sweden","institution_ids":["https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034579944","display_name":"David Bienvenue","orcid":"https://orcid.org/0000-0002-6115-3102","observed_orcids":["https://orcid.org/0000-0002-6115-3102"]},"institutions":[{"id":"https://openalex.org/I4210122457","display_name":"Aptevo Therapeutics (United states)","ror":"https://ror.org/02k8zdn75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Bienvenue","raw_affiliation_strings":["Aptevo Therapeutics Inc. , Seattle , Washington , USA"],"raw_orcid":"https://orcid.org/0000-0002-6115-3102","affiliations":[{"raw_affiliation_string":"Aptevo Therapeutics Inc. , Seattle , Washington , USA","institution_ids":["https://openalex.org/I4210122457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072019967","display_name":"Laura von Schantz","orcid":"https://orcid.org/0000-0003-1236-3135","observed_orcids":["https://orcid.org/0000-0003-1236-3135"]},"institutions":[{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Laura von Schantz","raw_affiliation_strings":["Alligator Bioscience AB , Lund , Sweden"],"raw_orcid":"https://orcid.org/0000-0003-1236-3135","affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB , Lund , Sweden","institution_ids":["https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043140596","display_name":"Catherine J. McMahan","orcid":"https://orcid.org/0000-0003-1767-6325","observed_orcids":["https://orcid.org/0000-0003-1767-6325"]},"institutions":[{"id":"https://openalex.org/I4210122457","display_name":"Aptevo Therapeutics (United states)","ror":"https://ror.org/02k8zdn75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Catherine J. McMahan","raw_affiliation_strings":["Aptevo Therapeutics Inc. , Seattle , Washington , USA"],"raw_orcid":"https://orcid.org/0000-0003-1767-6325","affiliations":[{"raw_affiliation_string":"Aptevo Therapeutics Inc. , Seattle , Washington , USA","institution_ids":["https://openalex.org/I4210122457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065270005","display_name":"Maria Askmyr","orcid":"https://orcid.org/0000-0001-6992-9940","observed_orcids":["https://orcid.org/0000-0001-6992-9940"]},"institutions":[{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Maria Askmyr","raw_affiliation_strings":["Alligator Bioscience AB , Lund , Sweden"],"raw_orcid":"https://orcid.org/0000-0001-6992-9940","affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB , Lund , Sweden","institution_ids":["https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087406110","display_name":"Gabriela Hern\u00e1ndez\u2010Hoyos","orcid":"https://orcid.org/0000-0003-0165-9715","observed_orcids":["https://orcid.org/0000-0003-0165-9715"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gabriela Hernandez-Hoyos","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-0165-9715","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5001191544","display_name":"Peter Ellmark","orcid":"https://orcid.org/0000-0002-6687-1250","observed_orcids":["https://orcid.org/0000-0002-6687-1250"]},"institutions":[{"id":"https://openalex.org/I187531555","display_name":"Lund University","ror":"https://ror.org/012a77v79","country_code":"SE","type":"education","lineage":["https://openalex.org/I187531555"]},{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Peter Ellmark","raw_affiliation_strings":["Alligator Bioscience AB , Lund , Sweden","Department of Immunotechnology , Lund University , Lund , Sweden"],"raw_orcid":"https://orcid.org/0000-0002-6687-1250","affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB , Lund , Sweden","institution_ids":["https://openalex.org/I4210130540"]},{"raw_affiliation_string":"Department of Immunotechnology , Lund University , Lund , Sweden","institution_ids":["https://openalex.org/I187531555"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.5971999764442444,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.5971999764442444,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.2078000009059906,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.08179999887943268,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/4-1bb","display_name":"4-1BB","score":0.8460000157356262},{"id":"https://openalex.org/keywords/5t4","display_name":"5T4","score":0.9539999961853027},{"id":"https://openalex.org/keywords/bispecific-t-cell-engagers","display_name":"bispecific T-cell engagers","score":0.8320000171661377},{"id":"https://openalex.org/keywords/t-cell-activation","display_name":"T cell activation","score":0.921999990940094},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.949999988079071},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.7059999704360962}],"concepts":[{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6220999956130981},{"id":"https://openalex.org/C3020495827","wikidata":"https://www.wikidata.org/wiki/Q426141","display_name":"Bispecific antibody","level":4,"score":0.4763999879360199},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4325999915599823},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4262999892234802},{"id":"https://openalex.org/C3020616263","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Tumor cells","level":2,"score":0.4018999934196472},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.2874000072479248},{"id":"https://openalex.org/C2776662205","wikidata":"https://www.wikidata.org/wiki/Q2459684","display_name":"Tumor antigen","level":4,"score":0.28220000863075256},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.27160000801086426},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2700999975204468},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.2614000141620636},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.2563000023365021},{"id":"https://openalex.org/C2993640289","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Solid tumor","level":3,"score":0.2506999969482422}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1535-7163.30734135","doi":"https://doi.org/10.1158/1535-7163.30734135","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.30734135","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Data_from_The_Bispecific_Tumor_Antigen-Conditional_4_1BB_x_5T4_Agonist_ALG_APV-527_Mediates_Strong_T-Cell_Activation_and_Potent_Antitumor_Activity_in_Preclinical_Studies/30734135/1/files/59895989.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/30734135","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Data_from_The_Bispecific_Tumor_Antigen-Conditional_4_1BB_x_5T4_Agonist_ALG_APV-527_Mediates_Strong_T-Cell_Activation_and_Potent_Antitumor_Activity_in_Preclinical_Studies/30734135","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.30734135","doi":"https://doi.org/10.1158/1535-7163.30734135","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.30734135","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Data_from_The_Bispecific_Tumor_Antigen-Conditional_4_1BB_x_5T4_Agonist_ALG_APV-527_Mediates_Strong_T-Cell_Activation_and_Potent_Antitumor_Activity_in_Preclinical_Studies/30734135/1/files/59895989.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9391000270843506,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4416740916.pdf","grobid_xml":"https://content.openalex.org/works/W4416740916.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4362486849","https://openalex.org/W4308399636","https://openalex.org/W3211750840","https://openalex.org/W3105274064","https://openalex.org/W2955824242","https://openalex.org/W4402559999","https://openalex.org/W4404053000","https://openalex.org/W4313359670","https://openalex.org/W1988413386","https://openalex.org/W4308400000"],"abstract_inverted_index":{"Supplementary":[0],"figures":[1],"and":[2],"methods":[3]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2025-11-28T00:00:00"}